about our product
Fighting the world’s organ shortage
SECORIM®-ABO enables transplantations across blood group barriers by specific removal of the organ recipient’s blood group anti-A and/or anti-B antibodies (ABO-antibodies)
SECORIM®-ABO has its potential in living-donor kidney transplantation with further use for other transplantations, such as liver, heart, lung, bone marrow and stem cells. Clinical results and data of transplantations performed after specific removal of incompatible ABO-antibodies by immunoadsorption in combination with immunosuppression report successful clinical outcomes similar to those of ABO compatible kidney transplantation, both short and long-term.
Selective immunoadsorption treatment, potentially increases the number of transplantations from living donors.
Specific removal of A and B antibodies, offering substantial advantage over other methods
The SECORIM®-ABO employs synthetic carbohydrate antigens immobilized on porous polymer beads to exclusively reduce the number of ABO-antibodies.
The specific removal of antibodies by SECORIM®-ABO prohibit several side effects compared to other pretreatment methods, e.g. plasma exchange. Specific antibody removal retains many valuable physiological plasma components.
Therefore, SECORIM®-ABO offers a substantial advantage compared to other methods.
